Organogenesis Holdings Management
Management criteria checks 2/4
Organogenesis Holdings' CEO is Gary Gillheeney, appointed in Jan 2014, has a tenure of 10.75 years. total yearly compensation is $6.24M, comprised of 14.6% salary and 85.4% bonuses, including company stock and options. directly owns 0.63% of the company’s shares, worth $2.66M. The average tenure of the management team and the board of directors is 7.1 years and 3.9 years respectively.
Key information
Gary Gillheeney
Chief executive officer
US$6.2m
Total compensation
| CEO salary percentage | 14.6% |
| CEO tenure | 10.8yrs |
| CEO ownership | 0.6% |
| Management average tenure | 7.1yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
Organogenesis: Lurking Disruption With Recovery To Follow
Oct 15Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S
Sep 09
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 15Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst
Jun 10Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality
May 21Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price
May 01Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
Apr 10These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Jan 04Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
May 31Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?
Jan 19Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio
Oct 18Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Sep 23Organogenesis gets FDA clearance for PuraPly MZ for wound healing
Aug 15Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors
Jul 28Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Jun 10Organogenesis Holdings: What Now
May 18The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet
Mar 31These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Mar 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$17m |
| Mar 31 2024 | n/a | n/a | US$6m |
| Dec 31 2023 | US$6m | US$909k | US$5m |
| Sep 30 2023 | n/a | n/a | US$13m |
| Jun 30 2023 | n/a | n/a | US$10m |
| Mar 31 2023 | n/a | n/a | US$13m |
| Dec 31 2022 | US$6m | US$883k | US$16m |
| Sep 30 2022 | n/a | n/a | US$59m |
| Jun 30 2022 | n/a | n/a | US$71m |
| Mar 31 2022 | n/a | n/a | US$83m |
| Dec 31 2021 | US$4m | US$835k | US$94m |
| Sep 30 2021 | n/a | n/a | US$62m |
| Jun 30 2021 | n/a | n/a | US$69m |
| Mar 31 2021 | n/a | n/a | US$43m |
| Dec 31 2020 | US$3m | US$823k | US$17m |
| Sep 30 2020 | n/a | n/a | -US$5m |
| Jun 30 2020 | n/a | n/a | -US$37m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$1m | US$819k | -US$39m |
| Sep 30 2019 | n/a | n/a | -US$46m |
| Jun 30 2019 | n/a | n/a | -US$48m |
| Mar 31 2019 | n/a | n/a | -US$58m |
| Dec 31 2018 | US$3m | US$798k | -US$65m |
| Sep 30 2018 | n/a | n/a | -US$60m |
| Jun 30 2018 | n/a | n/a | -US$52m |
| Mar 31 2018 | n/a | n/a | -US$32m |
| Dec 31 2017 | US$1m | US$780k | -US$9m |
Compensation vs Market: Gary's total compensation ($USD6.24M) is above average for companies of similar size in the US market ($USD2.40M).
Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.
CEO
Gary Gillheeney (69 yo)
10.8yrs
Tenure
US$6,244,671
Compensation
Mr. Gary S. Gillheeney, Sr. has been the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018 & serves as its Chair of the Board...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.8yrs | US$6.24m | 0.63% $ 2.7m | |
| Chief Financial Officer | 3.7yrs | US$1.63m | 0.048% $ 201.8k | |
| Chief Operating Officer | 7.1yrs | US$2.16m | 0.26% $ 1.1m | |
| Chief Administrative & Legal Officer | 7.8yrs | US$1.99m | 0.063% $ 265.2k | |
| Chief Commercial Officer | 7.1yrs | US$1.92m | 0.078% $ 328.1k | |
| Secretary | no data | no data | no data | |
| Vice President of Strategy | 3.8yrs | no data | 0.11% $ 441.6k |
7.1yrs
Average Tenure
57.5yo
Average Age
Experienced Management: ORGO's management team is seasoned and experienced (7.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.8yrs | US$6.24m | 0.63% $ 2.7m | |
| Director | 21.8yrs | no data | 11.29% $ 47.3m | |
| Director | 21.8yrs | no data | 11.5% $ 48.2m | |
| Lead Independent Director | 5.8yrs | US$291.46k | 0.10% $ 431.6k | |
| Director | 3.9yrs | no data | no data | |
| Independent Director | 3.4yrs | US$265.00k | 0.068% $ 283.9k | |
| Independent Director | 2.4yrs | US$226.98k | 0.068% $ 283.3k | |
| Independent Director | 2.9yrs | US$240.00k | 0.071% $ 296.6k | |
| Director | 3.9yrs | no data | no data | |
| Independent Director | 2.7yrs | US$230.52k | no data | |
| Independent Director | 2.4yrs | US$226.98k | 0.068% $ 283.3k |
3.9yrs
Average Tenure
59yo
Average Age
Experienced Board: ORGO's board of directors are considered experienced (3.9 years average tenure).